These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 32319676)
1. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer. Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676 [TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997 [TBL] [Abstract][Full Text] [Related]
3. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569 [TBL] [Abstract][Full Text] [Related]
4. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis. Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683 [TBL] [Abstract][Full Text] [Related]
5. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Mitchell AL; Gandhi A; Scott-Coombes D; Perros P J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer. van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318 [TBL] [Abstract][Full Text] [Related]
7. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613 [No Abstract] [Full Text] [Related]
8. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Jarzab B; Handkiewicz-Junak D; Wloch J Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322 [TBL] [Abstract][Full Text] [Related]
9. Radioiodine remnant ablation in low-risk differentiated thyroid cancer. Saengsuda Y J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318 [TBL] [Abstract][Full Text] [Related]
10. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles. Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474 [TBL] [Abstract][Full Text] [Related]
11. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. Patel SS; Goldfarb M J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391 [TBL] [Abstract][Full Text] [Related]
12. Treatment for microcarcinoma of the thyroid--clinical experience. Küçük NO; Tari P; Tokmak E; Aras G Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573 [TBL] [Abstract][Full Text] [Related]
13. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. Castagna MG; Cantara S; Pacini F J Endocrinol Invest; 2016 Oct; 39(10):1087-94. PubMed ID: 27350556 [TBL] [Abstract][Full Text] [Related]
15. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis. Ma C; Tang L; Fu H; Li J; Wang H Nucl Med Commun; 2013 Dec; 34(12):1150-6. PubMed ID: 24025918 [TBL] [Abstract][Full Text] [Related]
16. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer. Tian T; Jiang L; Zhang X; Huang R; Liu B Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335 [TBL] [Abstract][Full Text] [Related]
17. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650 [TBL] [Abstract][Full Text] [Related]
18. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer. Slonimsky E; Tulchinsky M Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402 [TBL] [Abstract][Full Text] [Related]
19. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
20. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. Lamartina L; Durante C; Lucisano G; Grani G; Bellantone R; Lombardi CP; Pontecorvi A; Arvat E; Felicetti F; Zatelli MC; Rossi R; Puxeddu E; Morelli S; Torlontano M; Crocetti U; Montesano T; Giubbini R; Orlandi F; Aimaretti G; Monzani F; Attard M; Francese C; Antonelli A; Limone P; Rossetto R; Fugazzola L; Meringolo D; Bruno R; Tumino S; Ceresini G; Centanni M; Monti S; Salvatore D; Spiazzi G; Mian C; Persani L; Barbaro D; Nicolucci A; Filetti S Thyroid; 2017 Dec; 27(12):1490-1497. PubMed ID: 29020892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]